Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared an article by Carlos Luri-Rey, et al. on X:
“Cross-priming is key in cancer immunotherapy.
- cDC1s cross-present tumor antigens & activate CD8+ T cells.
- Their abundance correlates with ICI response.
- FLT3L-based therapies show promise in trials.”
Cross-priming in cancer immunology and immunotherapy.
Authors: Carlos Luri-Rey, et al.
